Clinical Trial Update: A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects [Phase 1]

View source ↗

Summary

A Phase 1 safety and tolerability study of GSK2982772 in healthy male subjects, evaluating single-dose (fed and fasted) and repeat oral dosing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease

Drugs mentioned

• GSK2982772 (GSK2982772)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Inflammatory Bowel Diseases | Phase 1 | Status: COMPLETED